CN105902545B - Soimycin A用于制备白血病放化疗增敏剂的用途 - Google Patents
Soimycin A用于制备白血病放化疗增敏剂的用途 Download PDFInfo
- Publication number
- CN105902545B CN105902545B CN201610325180.XA CN201610325180A CN105902545B CN 105902545 B CN105902545 B CN 105902545B CN 201610325180 A CN201610325180 A CN 201610325180A CN 105902545 B CN105902545 B CN 105902545B
- Authority
- CN
- China
- Prior art keywords
- soimycin
- aml
- foxm1
- sensitizer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000032839 leukemia Diseases 0.000 title description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 40
- 230000035945 sensitivity Effects 0.000 claims abstract description 8
- 230000005855 radiation Effects 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003978 infusion fluid Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims 4
- 230000004083 survival effect Effects 0.000 abstract description 12
- 238000002512 chemotherapy Methods 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 208000025113 myeloid leukemia Diseases 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 25
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 229960002949 fluorouracil Drugs 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000001959 radiotherapy Methods 0.000 description 9
- 206010059866 Drug resistance Diseases 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000035572 chemosensitivity Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- AKFVOKPQHFBYCA-UHFFFAOYSA-N (1-L-valine)-[2-(2,3-didehydro-alanine)]-thiostrepton Natural products N=1C2C(N=3)=CSC=3C(C(C)OC(=O)C=3N=C4C(O)C(NC(C(C)C)C(=O)NC(=C)C(=O)NC(=C)C(=O)NC(C)C(=O)N5)C=CC4=C(C(C)O)C=3)NC(=O)C(N=3)=CSC=3C(C(C)(O)C(C)O)NC(=O)C(N=3)CSC=3C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=3)=CSC=3C25CCC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 AKFVOKPQHFBYCA-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- AKFVOKPQHFBYCA-KJULAZMPSA-N N-[3-[(3-amino-3-oxoprop-1-en-2-yl)amino]-3-oxoprop-1-en-2-yl]-2-[(1R,8S,11Z,15S,18S,25S,26R,35R,37S,46S,53S,59S)-18-[(2S,3R)-2,3-dihydroxybutan-2-yl]-11-ethylidene-59-hydroxy-8-[(1R)-1-hydroxyethyl]-31-[(1S)-1-hydroxyethyl]-26,46-dimethyl-40,43-dimethylidene-6,9,16,23,28,38,41,44,47-nonaoxo-37-propan-2-yl-27-oxa-3,13,20,56-tetrathia-7,10,17,24,36,39,42,45,48,52,58,61,62,63,64-pentadecazanonacyclo[23.23.9.329,35.12,5.112,15.119,22.154,57.01,53.032,60]tetrahexaconta-2(64),4,12(63),19(62),21,29(61),30,32(60),33,51,54,57-dodecaen-51-yl]-1,3-thiazole-4-carboxamide Chemical compound C/C=C\1/C2=N[C@H](CS2)C(=O)N[C@H](C3=NC(=CS3)C(=O)N[C@H]4[C@H](OC(=O)C5=NC6=C(C=C[C@H]([C@@H]6O)N[C@H](C(=O)NC(=C)C(=O)NC(=C)C(=O)N[C@H](C(=O)N[C@@]7(CCC(=N[C@@H]7C8=CSC4=N8)C9=NC(=CS9)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)C2=NC(=CS2)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)C)C(C)C)C(=C5)[C@H](C)O)C)[C@@](C)([C@@H](C)O)O AKFVOKPQHFBYCA-KJULAZMPSA-N 0.000 description 2
- STTJBBWRTRUGII-UHFFFAOYSA-N Siomycin A Natural products CC=C1/NC(=O)C(NC(=O)c2csc(n2)C34CCC(=NC3c5csc(n5)C(NC(=O)c6csc(n6)C(NC(=O)C7CSC1=N7)C(C)(O)C(C)O)C(C)OC(=O)c8cc(C(C)O)c9C=CC(NC(C(C)C)C(=O)NC(=C)C(=O)NC(=C)C(=O)NC(C)C(=O)N4)C(O)c9n8)c%10nc(cs%10)C(=O)N)C(C)O STTJBBWRTRUGII-UHFFFAOYSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108010057354 siomycin A Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种Soimycin A制备急性髓性白血病(Acute myeloid leukemia,AML)放化疗增敏剂的用途。本发明的体外及动物实验表明,Soimycin A具有提高AML细胞系HL‑60及慢性髓性白血病(Chromic myeloid leukemia,CML)细胞系K562放疗敏感性的作用,并证实Soimycin A具有提高HL‑60细胞移植构建的AML小鼠化疗后存活率的作用。本发明所述增敏剂用于急性髓性白血病放化疗的应用前景好。
Description
技术领域
本发明涉及Soimycin A用于制备急性髓性白血病放化疗增敏剂的用途
背景技术
急性髓性白血病(Acute myeloid leukemia,AML)是白血病中最常见的一类恶性克隆性疾病,AML主要表现为造血干细胞异常增殖、分化障碍、凋亡受阻而停滞于不完全成熟的各阶段,并广泛侵润骨髓及其它器官和组织。现阶段急性髓性白血病的治疗以化疗为主,辅以放疗。化疗药物主要通过干扰DNA合成,抑制肿瘤细胞快速增殖分裂;放射性治疗通过电离辐射产生大量能量,进而破坏肿瘤细胞染色体结构,使细胞生长停止。尽管近年来新的化疗药物不断出现,放化疗方案不断改进,但仍有50~80%的AML患者在获得完全缓解后出现复发现象,并最终发展为难治性白血病。究其原因主要在于肿瘤细胞产生耐药性及放射性抵抗。
放化疗增敏是指采用微小剂量的该物质与放疗/化疗联合使用即能显著提高放化疗效果,在肿瘤治疗中低毒高效的放化疗增敏剂具有广泛的应用前景。因此,深入探究AML肿瘤细胞耐药性及放射性抵抗的分子机制,并寻找高效放化疗增敏剂是治疗AML亟待解决的问题之一。
研究发现肿瘤细胞耐药性及放射性抵抗的产生与一系列基因被诱导表达紧密相关。FoxM1(Forkhead-box M1)是转录因子forkhead家族成员之一。FoxM1在调节细胞增殖,细胞周期进程,分化,DNA损伤修复及细胞凋亡中发挥重要作用。FoxM1是实体瘤中最常见表达上调的基因之一,在结肠癌、肝癌、前列腺癌和乳腺癌等多种肿瘤中检测到其高表达,说明FoxM1与肿瘤发生具有紧密联系。最新的研究发现,FoxM1介导了部分肿瘤细胞的耐药性,干扰FoxM1的表达后肿瘤细胞化疗敏感性增加。但FoxM1是否介导了AML肿瘤细胞耐药性及放射性抵抗仍不明晰,FoxM1是否可作为AML放化疗增敏剂的干预靶点尚不清楚。
Soimycin A是一种天然噻唑类抗生素,其分子式为C71H81N19O18S5,分子量为1648.84,并具有以下结构
研究证实Soimycin A可以抑制FoxM1在mRNA及蛋白水平的表达,并影响FoxM1下游靶基因的转录。Soimycin A对AML肿瘤细胞的影响尚不清楚,我们在探究FoxM1基因对小鼠骨髓细胞耐药性(5-氟尿嘧啶核苷)的影响研究中,发现Soimycin A能够提高AML细胞系放疗敏感性及AML小鼠化疗敏感性,该结果目前尚未见国内外报道。
发明内容
本发明的目的是提供一种针对FoxM1靶点的Soimycin A用于制备AML放化疗增敏剂的用途,该增敏剂提高AML细胞系放疗敏感性及AML小鼠化疗后生存率疗效明显。在目前临床上缺乏高效AML放化疗增敏剂的前提下,Soimycin A应用前景好。
本发明的技术方案是:
Soimycin A在制备急性髓性白血病放化疗增敏剂中的应用。
所述白血病是急性髓性白血病。
所述增敏剂通过抑制FoxM1的表达提高AML细胞系放疗及AML小鼠化疗敏感性。
本发明所述增敏剂,可不经过口服给药,以注射剂或输液剂等形式给药,给药量以每公斤体重每12小时20~40mg为宜。
发明人经研究发现所述Soimycin A在体外对AML细胞系HL-60及CML细胞系K562具有提高放疗敏感性的作用。结合小鼠实验,在AML小鼠模型中观察证实Soimycin A具有提高化疗敏感性的作用。
Soimycin A作为一种已知化合物可通过本领域已知方法制备或从市场上获得,因此来源方便,成本较低。
以下的实验实施例是对本发明的进一步详细说明但不意味着对本发明的限制。
附图说明
图1为5-氟尿嘧啶对FoxM1基因敲除型小鼠生存率的影响;
图2为Soimycin A预处理对髓性白血病细胞系放疗后凋亡率的影响;
图3为Soimycin A预处理对AML小鼠化疗后生存率的影响。
具体实施方式
人AML细胞系HL-60及CML细胞系K562购自ATCC公司;
NSGS受体小鼠购自中国人民解放军第三军医大学实验动物中心;
本实施例实验所用DMEM培养基及新生牛血清购自Gibco公司;
本实施例实验所用Soimycin A购自美国Sigma公司;
5-氟尿嘧啶购自Sigma公司;
Annexin-PI凋亡试剂盒购自BD公司;
本实施例实验所用其它试剂为市售的分析纯试剂。
实施例1:5-FU对FoxM1基因敲除型小鼠生存率的影响
1.1实验方法:
FoxM1f1/f1Tie2Cre为FoxM1基因敲除型小鼠,FoxM1f1/f1为对照小鼠,Tie2Cre在不需要诱导物的情况下可以介导靶基因在内皮和造血系统的敲除,且敲除能够在整个造血过程中维持。分别选取一定数量的FoxM1f1/f1小鼠(共11只)及FoxM1f1/f1Tie2Cre小鼠(共12只),通过腹腔注射5-氟尿嘧啶(150mg/kg)后,在6天及16天时再次注射,连续监测小鼠存活率。
1.2实验结果:
5-氟尿嘧啶是一种干扰DNA合成的广谱抗肿瘤药物,二次注射5-氟尿嘧啶后FoxM1f1/f1小鼠未出现死亡现象,三次注射5-氟尿嘧啶后FoxM1f1/f1小鼠存活率小幅降至90%。而FoxM1f1/f1Tie2Cre小鼠二次注射5-氟尿嘧啶后,在11天时开始出现急剧死亡现象,在三次注射前存活率已低于10%,P值小于0.0001,说明FoxM1部分介导了小鼠骨髓细胞的5-氟尿嘧啶耐药性,提示FoxM1可作为放化疗增敏剂的潜在靶点(参见图1)。
实施例2:Soimycin A预处理对髓性白血病细胞系放疗后凋亡率的影响
2.1实验方法:
分别接种K562及HL-60细胞系,分别利用0.5%DMSO及Soimycin A(0.5μM)预处理18小时,一组细胞利用总量为2Gy的放射性射线处理(0.5Gy/min),另一组细胞静置,随后继续培养12小时。收集细胞后,Annexin V及DAPI双染色,流式细胞仪分析检测。
2.2实验结果:
DMSO预处理组K562及HL-60细胞经放疗后凋亡率分别由7%、8%升高至31%、41%。而Soimycin A预处理组K562及HL-60细胞经放疗后凋亡率分别由8%、8%升高至59%、76%。说明Soimycin A预处理可明显提高AML细胞系HL-60及CML细胞系K562放疗敏感性,且对HL-60细胞放疗增敏效果更为显著(参见图2)。
实施例3:Soimycin A预处理对髓性白血病小鼠化疗后生存率的影响
3.1实验方法:
一共20只NSGS受体小鼠进行2.5Gy的辐照,每个受体小鼠通过尾静脉注射0.2×106HL-60细胞,7天之后将受体小鼠分为两组各10个,进行5-氟尿嘧啶处理(150mg/kg),其中一组注射5-氟尿嘧啶前24小时内注射两次DMSO作为对照组(12小时一次),另外一组尾静脉注射两次Siomycin A(30mg/kg,12小时一次),连续监测小鼠存活率。
3.2实验结果:
HL-60细胞移植构建的AML小鼠在接受5-氟尿嘧啶治疗前利用DMSO预处理,小鼠在23天时开始出现急剧死亡现象,在32天时全部死亡,而Soimycin A预处理组小鼠在25天时出现死亡现象,40天时尚有小鼠存活,p值小于0.05。说明Soimycin A可明显提高AML小鼠5-氟尿嘧啶治疗后存活率,证实Soimycin A具有AML小鼠化疗增敏的作用(参见图3)。
结论:FoxM1部分介导了小鼠骨髓细胞对5-氟尿嘧啶的耐药性,Siomycin A通过抑制FoxM1表达明显提高AML细胞系HL-60放疗敏感性,并提高HL-60细胞移植构建的AML小鼠化疗敏感性。
Claims (4)
1. Soimycin A在用于急性髓性白血病放疗增敏剂中的用途。
2.根据权利要求1所述的用途,其特征在于:所述放疗增敏剂通过抑制FoxM1的表达提高AML细胞系HL-60的放疗敏感性。
3.根据权利要求1所述的用途,其特征在于:所述放疗增敏剂以注射剂或输液剂给药。
4.根据权利要求1所述的用途,其特征在于:利用Soimycin A制备的放疗增敏剂用量为每公斤每12小时20~40mg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610325180.XA CN105902545B (zh) | 2016-05-17 | 2016-05-17 | Soimycin A用于制备白血病放化疗增敏剂的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610325180.XA CN105902545B (zh) | 2016-05-17 | 2016-05-17 | Soimycin A用于制备白血病放化疗增敏剂的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105902545A CN105902545A (zh) | 2016-08-31 |
CN105902545B true CN105902545B (zh) | 2018-10-16 |
Family
ID=56749308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610325180.XA Expired - Fee Related CN105902545B (zh) | 2016-05-17 | 2016-05-17 | Soimycin A用于制备白血病放化疗增敏剂的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105902545B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7348074B2 (ja) * | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | がん治療に対する個別化応答の予測方法およびそのキット |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127297A1 (en) * | 2010-04-07 | 2011-10-13 | The Board Of Trustees Of The University Of Illinois | Method of treating tumor resistant to herceptin or paclitaxel using foxm1 inhibitors and detecting same |
-
2016
- 2016-05-17 CN CN201610325180.XA patent/CN105902545B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011127297A1 (en) * | 2010-04-07 | 2011-10-13 | The Board Of Trustees Of The University Of Illinois | Method of treating tumor resistant to herceptin or paclitaxel using foxm1 inhibitors and detecting same |
Non-Patent Citations (1)
Title |
---|
Targeting FoxM1 transcription factor in T-cell acute lymphoblastic leukemia cell line;Tüfekci等;《Leukemia Research》;20141217;第39卷(第3期);第342-347页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105902545A (zh) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leiker et al. | Radiation enhancement of head and neck squamous cell carcinoma by the dual PI3K/mTOR inhibitor PF-05212384 | |
US20070281040A1 (en) | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents | |
Tsai et al. | S onic H edgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma | |
Ma et al. | Targeted glucose or glutamine metabolic therapy combined with PD-1/PD-L1 checkpoint blockade immunotherapy for the treatment of tumors-mechanisms and strategies | |
Liu et al. | Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo | |
CN105233292A (zh) | Ory-1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途 | |
Zhai et al. | Radiotherapy: Brightness and darkness in the era of immunotherapy | |
Ma et al. | Antineoplastic agents in chemotherapy facilitating tumor growth and angiogenesis in the interval administrations | |
CN105902545B (zh) | Soimycin A用于制备白血病放化疗增敏剂的用途 | |
Liu et al. | Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy | |
Rong et al. | Lobaplatin enhances radioactive 125I seed-induced apoptosis and anti-proliferative effect in non-small cell lung cancer by suppressing the AKT/mTOR pathway | |
CN102499942A (zh) | 雷公藤甲素顺铂联合运用在制备抗耐药性胰腺癌药物中的应用 | |
Wiedemann et al. | Radiation-induced cardiac side-effects: The lung as target for interacting damage and intervention | |
CN106265760A (zh) | 戈氏梭菌驯化株在制备放疗增敏剂中的应用 | |
Lei et al. | Combined treatment of radiotherapy and immunotherapy for urological malignancies: current evidence and clinical considerations | |
KR101858128B1 (ko) | Sulf2 억제제를 포함하는 방사선 내성 암의 치료용 약학 조성물 | |
Colangelo et al. | Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions | |
CN113456659A (zh) | 一种银椴苷与索拉菲尼的组合物及用于制备抗肝癌药物的用途 | |
Long et al. | The progress of microenvironment-targeted therapies in brain metastases | |
CN112656785A (zh) | 槲皮素在制备前列腺癌放疗增敏药物中的用途 | |
CN105497900A (zh) | 一种抗未分化甲状腺癌耐药靶点及其应用 | |
Brock et al. | Modification by dexamethasone of radiation response of in vitro cultured cells | |
CN103099809A (zh) | 一种治疗三阴性乳腺癌的药物组合物及其应用 | |
Zhao | Mechanistic of RBM3 Regulating Rad51 Alternative Splicing Mediated DNA Damage Repair Promoting Radioresistance of Nasopharyngeal Carcinoma | |
Barranco et al. | Activity of intestinal efflux pumps in M-406 mammary adenocarcinoma bearing mice with metabolic syndrome treated with cyclophosphamide metronomic chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181016 |
|
CF01 | Termination of patent right due to non-payment of annual fee |